HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Putnam, W. S. Articles by Benet, L. Z. Search for Related Content PubMed PubMed Citation Articles by Putnam, W. S. Articles by Benet, L. Z. Social Bookmarking                         What's this?

Effect of the MDR1 C3435T Variant and P-Glycoprotein Induction on Dicloxacillin Pharmacokinetics

From the Department of Biopharmaceutical Sciences, School of Pharmacy (Dr Putnam, Dr Benet); Genomics Core Facility, Department of Biochemistry and Biophysics (Mr Woo); and Drug Studies Unit, School of Pharmacy (Dr Huang), University of California, San Francisco.

This study investigated 2 hypotheses about genotype-phenotype relationships for the efflux transporter, P-glycoprotein: (1) the presence of a synonymous C3435T variant in exon 26 of the MDR1 gene correlates to higher plasma concentrations of a P-glycoprotein substrate, dicloxacillin, and (2) the effects of genotypic differences decrease under conditions of P-glycoprotein induction by rifampin. Eighteen healthy volunteers received two 1-g doses of dicloxacillin, one on the 1st study day and the other on the 11th day of rifampin dosing (600 mg daily). Dicloxacillin and its 5-hydroxymethyl metabolite were analyzed using liquid chromatography/tandem mass spectrometry. Mean dicloxacillin C_max measurements were 30.5 ± 13.5, 33.3 ± 4.7, and 31.1 ± 12.8 µg/mL in individuals with the CC, CT, and TT genotype at position 3435 in exon 26 of the MDR1 gene. Following rifampin dosing, the mean dicloxacillin C_max across genotypes decreased from 31.4 ± 10.8 to 22.9 ± 7.0µg/mL (P < .05), whereas the mean oral clearance increased from 235 ± 82 to 297 ± 71 mL/min (P < .001), and the mean absorption time increased from 0.71 ± 0.55 to 1.34 ± 0.77 h (P < .05). Rifampin treatment increased the formation clearance, C_max, and AUC of the 5-hydroxymethyl metabolite by 135%, 119%, and 59%, respectively. The C3435T variant had no effect on dicloxacillin pharmacokinetics. The data suggested that rifampin induced intestinal P-glycoprotein and increased dicloxacillin metabolism.

Key Words: MDR1 variant • P-glycoprotein • dicloxacillin • pharmacokinetics

Address for reprints: Leslie Z. Benet, PhD, Department of Biopharmaceutical Sciences, University of California, San Francisco, 513 Parnassus Avenue, Room U-68, San Francisco, CA 94143-0446.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Sandberg, J. H. R. Hessler, R. L. Skov, J. Blom, and N. Frimodt-Moller Intracellular Activity of Antibiotics against Staphylococcus aureus in a Mouse Peritonitis Model Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1874 - 1883. [Abstract] [Full Text] [PDF]

				M. Weiner, W. Burman, C.-C. Luo, C. A. Peloquin, M. Engle, S. Goldberg, V. Agarwal, and A. Vernon Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2861 - 2866. [Abstract] [Full Text] [PDF]

				S. Choudhuri and C. D. Klaassen Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters International Journal of Toxicology, July 1, 2006; 25(4): 231 - 259. [Abstract] [Full Text] [PDF]